A Phase 3 interventional study of Fezolinetant and placebo in Hot Flashes, sponsored by Astellas Pharma Global Development, Inc.. Completed at 93 sites in 7 countries. Open to female participants aged 40 Years to 65 Years. Per ClinicalTrials.gov, last updated 2024-11-05.
Sponsored by Astellas Pharma Global Development, Inc. (part of Astellas Pharma Inc) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies testing fezolinetant in Hot Flashes — 4 open to participants now, 5 under way, 4 of them phase 3. fezolinetant · Hot Flashes.
Among the 16 studies testing fezolinetant in Hot Flashes, this one is the 4th largest by enrollment, is one of 3 that started in 2019, is one of 10 in phase 3, and was the 2nd registered.
339 studies on the registry are indexed under Hot Flashes; 56 are open to participants now.
Browse Hot Flashes studies →4 of the 16 studies testing fezolinetant in Hot Flashes are open now, in 2 countries. Recruiting first, the newest first:
Astellas Pharma Inc · Sites in India
Ages 18+ · Women only
University of Colorado, Denver · Sites in United States
Ages 45–55 · Women only · Healthy volunteers
University of Vermont · Sites in United States
Ages 18+ · Men only
Rebecca Thurston · Sites in United States
Ages 40–65 · Women only
By country, each count listing its studies:
fezolinetant: first FDA approval 2023 (VEOZAH), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →
Of the 36 Hot Flashes studies recruiting now, 13 (36%) set no upper age limit and 21 (58%) stop at 75 or younger; 2 take children under 18; 11 take healthy volunteers.
This study: 40 Years to 65 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 6 · Phase 3 11
First in 2015; this study’s year is marked. 3 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 501 is above the median of 90 across 306 interventional studies indexed under Hot Flashes.
Median enrollment 249 across the 16 interventional studies. Of the 11 that completed or were terminated, 5 (45%) have results posted.
This tab as a report to print or save as PDF → With an account.
13 of 16 have an industry lead sponsor. The 7 most frequent:
This study is registered under Astellas Pharma Global Development, Inc., one of the names counted as Astellas Pharma Inc. Under that name alone:
Astellas Pharma Global Development, Inc. is the lead sponsor of 207 studies on the registry; 23 are open to participants now.
Of its 82 completed or terminated interventional studies of FDA-regulated products, 38 (46%) have results posted.
16 studies in Hot Flashes by Astellas Pharma Inc: 2 open now, 3 under way, 2 of them phase 3. Of 13 finished, 5 (38%) have results posted.
Among the 16 studies in Hot Flashes by Astellas Pharma Inc, this one is the 4th largest by enrollment of the 13 interventional ones that give a count, is one of 3 that started in 2019, is one of 9 in phase 3, and was the 2nd registered.
Astellas Pharma Inc’s Hot Flashes studies by the year they started, since 2015.
1 of the studies testing fezolinetant in Hot Flashes that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06972875University of VermontFezolinetant for Treating Hot Flashes in Men With Prostate Cancer | 2027-01 |
Add it to your calendar (.ics) → With an account.
Among the 16 studies testing fezolinetant in Hot Flashes, from their registry updates:
Among Astellas Pharma Inc’s 16 in Hot Flashes:
This tab as a report to print or save as PDF → With an account.
This study was for women in menopause with moderate to severe hot flashes. Menopause, a normal part of aging, is the time of a woman's last period. Hot flashes can interrupt a woman's daily life.
The study treatments are fezolinetant 30 mg (1 tablet of fezolinetant and 1 placebo tablet) once a day, fezolinetant 45 mg (2 tablets of fezolinetant) once a day or placebo (2 tablets) once a day. (Placebo is a dummy treatment that looks like medicine but does not have any medicine in it.) The study compared fezolinetant and placebo after 4 and 12 weeks of dosing. The study evaluated if fezolinetant reduces the number of hot flashes and the study evaluated if fezolinetant reduces the severity of the hot flashes.
Women in the study received an electronic handheld device at the first study visit. (It is similar to a smart phone.) Each day of the study, study participants used this to record their hot flashes. Their record for the 10 days before the start of study treatment was checked. They remained in the study if their record shows 7 or 8 moderate to severe hot flashes per day (50 or more per week). Next, they were picked for 1 of the 2 study treatments (fezolinetant or placebo) by chance alone. It is like flipping a coin.
The study participants took study treatment for 52 weeks. The first 12 weeks of study treatment was "double-blinded." That means that the study participants and the study doctors did not know who took which of the study treatments (fezolinetant 30 mg, fezolinetant 45 mg or placebo) during that time. The last 40 weeks of study treatment was "noncontrolled." That means that each study participant and the study doctors knew which study treatment that study participant took during that time. Women who took fezolinetant during the first 12 weeks continued to take the same dose. Women who took placebo during the first 12 weeks took fezolinetant. Their dose was either 30 mg or 45 mg fezolinetant.
At weeks 2, 4, 8, 12, 14, 16 and then once a month, the study participants went to the hospital or clinic for a check-up. They were asked about medications, side effects and how they felt. Other checks included physical exam and vital signs (heart rate, temperature and blood pressure). Blood and urine was collected for laboratory tests. Study participants completed questionnaires that were about how hot flashes affect their daily life. Study participants who had their uterus had the following 2 tests done at the first and last study visits. One of the 2 tests was endometrial biopsy. This test involved removing a small amount of tissue from the inside lining of the uterus. The tissue was then checked under a microscope. The other test was transvaginal ultrasound. This test used sound waves to create pictures of the organs in the pelvis. The sound waves are transmitted by a probe (transducer), which was placed inside the vagina. Study participants might have a screening mammogram done at the first and/or last study visit. A mammogram is an x-ray picture of the breasts used to screen for breast cancer. Study participants who did not have this test done in the last 12 months had it done at the first study visit. They had done at the last study visit if they were due for their screening mammogram and their own doctor agrees.
The last check-up at the hospital or clinic was 3 weeks after the last dose of study treatment.
This study consisted of a screening period and a 52 week treatment period. Safety follow up occurred 3 weeks after the last dose of study drug.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Subject must be seeking treatment or relief for vasomotor symptoms (VMS) associated with menopause and confirmed as menopausal per 1 of the following criteria at the screening visit:
Exclusion Criteria:
Subject's systolic blood pressure is ≥ 130 mmHg or diastolic blood pressure is ≥ 80 mmHg based on the average of 2 to 3 readings, on at least 2 different occasions within the screening period.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received fezolinetant 30 mg (one 30 mg fezolinetant tablet and one placebo tablet) orally, QD up to week 12 during double-blind treatment period followed by fezolinetant 30 mg orally, QD from week 13 up to Week 52 during extension treatment period.
Drug: Fezolinetant
Participants received fezolinetant 45 mg (one 30 mg tablet and one 15 mg tablet) orally, QD up to week 12 during double-blind treatment period followed by fezolinetant 45 mg orally, QD from week 13 up to Week 52 during extension treatment period.
Drug: Fezolinetant
Participants received fezolinetant matching placebo (two fezolinetant matching placebo tablets) orally, once daily (QD) up to week 12 during double-blind treatment period.
Drug: placebo
Participants who received placebo during double-blind treatment period were re-randomized to receive fezolinetant 30 mg orally, QD from week 13 up to week 52 during extension treatment period.
Drug: Fezolinetant
Participants who received placebo during double-blind treatment period were re-randomized to receive fezolinetant 45 mg orally, QD from week 13 up to week 52 during extension treatment period.
Drug: Fezolinetant
Oral tablet
Oral Tablet
Change From Baseline in The Mean Frequency of Moderate to Severe VMS at Week 4
The frequency of moderate to severe VMS was the number of moderate to severe VMS per 24 hours. A daily frequency per week was derived by taking the mean of the data over 7 days. Moderate VMS was defined as sensation of heat with sweating/dampness, but was able to continue activity. If at night, participant woke up because she was feeling hot and/or was sweating, but no action was necessary other than rearranging the bed sheets. Severe VMS was defined as sensation of intense heat with sweating, caused disruption of activity. If at night, participant woke up hot and was sweating and needed to take action (e.g., remove layers of clothes, open the window, or get out of bed). Baseline was the average number of moderate to severe VMS per 24 hours based on the non-missing values in the 10 days immediately prior to randomization.
Time frame: Baseline and week 4
Change From Baseline in The Mean Frequency of Moderate to Severe VMS at Week 12
The frequency of moderate to severe VMS was the number of moderate to severe VMS per 24 hours. A daily frequency per week was derived by taking the mean of the data over 7 days. Moderate VMS was defined as sensation of heat with sweating/dampness, but was able to continue activity. If at night, participant woke up because she was feeling hot and/or was sweating, but no action was necessary other than rearranging the bed sheets. Severe VMS was defined as sensation of intense heat with sweating, caused disruption of activity. If at night, participant woke up hot and was sweating and needed to take action (e.g., remove layers of clothes, open the window, or get out of bed). Baseline was the average number of moderate to severe VMS per 24 hours based on the non-missing values in the 10 days immediately prior to randomization.
Time frame: Baseline and week 12
Change From Baseline in The Mean Severity of Moderate to Severe VMS at Week 4
Severity of moderate to severe VMS per day at post baseline visit was calculated as follows: \[(number of mild hot flashes per day x 1) + (number of moderate hot flashes per day x 2) + (number of severe hot flashes per day x 3)\]/Total number of daily mild/moderate/severe hot flashes Moderate VMS was defined as sensation of heat with sweating/dampness, but was able to continue activity. If at night, participant woke up because she was feeling hot and/or was sweating, but no action was necessary other than rearranging the bed sheets. Severe VMS was defined as sensation of intense heat with sweating, caused disruption of activity. If at night, participant woke up hot and was sweating and needed to take action (e.g., remove layers of clothes, open the window, or get out of bed). Severity was zero for participants that had no mild or moderate or severe VMS. Higher scores indicates greater severity.
Time frame: Baseline and week 4
Change From Baseline in The Mean Severity of Moderate to Severe VMS at Week 12
Severity of moderate to severe VMS per day at post baseline visit was calculated as follows: \[(number of mild hot flashes per day x 1) + (number of moderate hot flashes per day x 2) + (number of severe hot flashes per day x 3)\]/Total number of daily mild/moderate/severe hot flashes Moderate VMS was defined as sensation of heat with sweating/dampness, but was able to continue activity. If at night, participant woke up because she was feeling hot and/or was sweating, but no action was necessary other than rearranging the bed sheets. Severe VMS was defined as sensation of intense heat with sweating, caused disruption of activity. If at night, participant woke up hot and was sweating and needed to take action (e.g., remove layers of clothes, open the window, or get out of bed). Severity was zero for participants that had no mild or moderate or severe VMS. Higher scores indicates greater severity.
Time frame: Baseline and week 12
Change From Baseline in The Mean Patient-reported Outcomes Measurement Information System Sleep Disturbance - Short Form 8b (PROMIS SD SF 8b) Total Score at Week 12
The PROMIS SD SF 8b assesses self-reported sleep disturbance over the past 7 days and includes perceptions of restless sleep; satisfaction with sleep; refreshing sleep; difficulties sleeping, getting to sleep or staying asleep; amount of sleep; and sleep quality. Because it assesses the participants experience of sleep disturbance, the measure does not focus on specific sleep-disorder symptoms or ask participants to report objective measures of sleep (e.g., total amount of sleep, time to fall asleep and amount of wakefulness during sleep). Responses to each of the 8 items range from 1 (no disturbed sleep) to 5 (disturbed sleep), and the range of possible summed raw scores is 8 to 40. Higher scores on the PROMIS SD SF 8b indicate more of the disturbed sleep.
Time frame: Baseline and week 12
Change From Baseline in The Mean Frequency of Moderate, and Severe VMS to Each Study Week Up to Week 12
The frequency of moderate to severe VMS was the number of moderate to severe VMS per 24 hours. A daily frequency per week was derived by taking the mean of the data over 7 days. Moderate VMS was defined as sensation of heat with sweating/dampness, but was able to continue activity. If at night, participant woke up because she was feeling hot and/or was sweating, but no action was necessary other than rearranging the bed sheets. Severe VMS was defined as sensation of intense heat with sweating, caused disruption of activity. If at night, participant woke up hot and was sweating and needed to take action (e.g., remove layers of clothes, open the window, or get out of bed). Baseline was the average number of moderate to severe VMS per 24 hours based on the non-missing values in the 10 days immediately prior to randomization.
Time frame: Baseline and weeks 1, 2, 3, 5, 6, 7, 8, 9, 10, and 11
Change From Baseline in The Mean Severity of Moderate, and Severe VMS to Each Study Week Up to Week 12
Severity of moderate to severe VMS per day at post baseline visit was calculated as follows: \[(number of mild hot flashes per day x 1) + (number of moderate hot flashes per day x 2) + (number of severe hot flashes per day x 3)\]/Total number of daily mild/moderate/severe hot flashes Moderate VMS was defined as sensation of heat with sweating/dampness, but was able to continue activity. If at night, participant woke up because she was feeling hot and/or was sweating, but no action was necessary other than rearranging the bed sheets. Severe VMS was defined as sensation of intense heat with sweating, caused disruption of activity. If at night, participant woke up hot and was sweating and needed to take action (e.g., remove layers of clothes, open the window, or get out of bed). Severity was zero for participants that had no mild or moderate or severe VMS. Higher scores indicates greater severity.
Time frame: Baseline and weeks 1, 2, 3, 5, 6, 7, 8, 9, 10 and 11
Mean Percent Change in The Frequency of Moderate And Severe Vasomotor Symptoms From Baseline to Each Study Week Up to Week 12
The frequency of moderate to severe VMS was the number of moderate to severe VMS per 24 hours. A daily frequency per week was derived by taking the mean of the data over 7 days. Moderate VMS was defined as sensation of heat with sweating/dampness, but was able to continue activity. If at night, participant woke up because she was feeling hot and/or was sweating, but no action was necessary other than rearranging the bed sheets. Severe VMS was defined as sensation of intense heat with sweating, caused disruption of activity. If at night, participant woke up hot and was sweating and needed to take action (e.g., remove layers of clothes, open the window, or get out of bed). Baseline was the average number of moderate to severe VMS per 24 hours based on the non-missing values in the 10 days immediately prior to randomization.
Time frame: Baseline and weeks 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 and 12
Number of Participants With Percent Reduction of >=50% in the Mean Frequency of Moderate and Severe VMS From Baseline to Each Study Week Up to Week 12
The frequency of moderate to severe VMS was the number of moderate to severe VMS per 24 hours. A daily frequency per week was derived by taking the mean of the data over 7 days. Moderate VMS was defined as sensation of heat with sweating/dampness, but was able to continue activity. If at night, participant woke up because she was feeling hot and/or was sweating, but no action was necessary other than rearranging the bed sheets. Severe VMS was defined as sensation of intense heat with sweating, caused disruption of activity. If at night, participant woke up hot and was sweating and needed to take action (e.g., remove layers of clothes, open the window, or get out of bed). Baseline was the average number of moderate to severe VMS per 24 hours based on the non-missing values in the 10 days immediately prior to randomization. Participant has \>=50% reduction from baseline to each post baseline week for the frequency of moderate to severe VMS.
Time frame: Baseline and weeks 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 and 12
Number of Participants With Mean Percent Reduction of 100% in The Mean Frequency of Moderate, and Severe VMS From Baseline to Each Study Week Up to Week 12
The frequency of moderate to severe VMS was the number of moderate to severe VMS per 24 hours. A daily frequency per week was derived by taking the mean of the data over 7 days. Moderate VMS was defined as sensation of heat with sweating/dampness, but was able to continue activity. If at night, participant woke up because she was feeling hot and/or was sweating, but no action was necessary other than rearranging the bed sheets. Severe VMS was defined as sensation of intense heat with sweating, caused disruption of activity. If at night, participant woke up hot and was sweating and needed to take action (e.g., remove layers of clothes, open the window, or get out of bed). Baseline was the average number of moderate to severe VMS per 24 hours based on the non-missing values in the 10 days immediately prior to randomization. Participant has 100% reduction from baseline to each post baseline week for the frequency of moderate to severe VMS.
Time frame: Baseline and weeks 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 and 12
Change From Baseline in The Mean Frequency of Moderate, and Severe VMS at Week 24
The frequency of moderate to severe VMS was the number of moderate to severe VMS per 24 hours. A daily frequency per week was derived by taking the mean of the data over 7 days. Moderate VMS was defined as sensation of heat with sweating/dampness, but was able to continue activity. If at night, participant woke up because she was feeling hot and/or was sweating, but no action was necessary other than rearranging the bed sheets. Severe VMS was defined as sensation of intense heat with sweating, caused disruption of activity. If at night, participant woke up hot and was sweating and needed to take action (e.g., remove layers of clothes, open the window, or get out of bed). Baseline was the average number of moderate to severe VMS per 24 hours based on the non-missing values in the 10 days immediately prior to randomization.
Time frame: Baseline and 24 weeks of fezolinetant exposure (week 36 for arms Placebo/Fezolinetant 30 mg and Placebo/Fezolinetant 45 mg)
Change From Baseline in The Mean Severity of Moderate, and Severe VMS at Week 24
Severity of moderate to severe VMS per day at post baseline visit was calculated as follows: \[(number of mild hot flashes per day x 1) + (number of moderate hot flashes per day x 2) + (number of severe hot flashes per day x 3)\]/Total number of daily mild/moderate/severe hot flashes Moderate VMS was defined as sensation of heat with sweating/dampness, but was able to continue activity. If at night, participant woke up because she was feeling hot and/or was sweating, but no action was necessary other than rearranging the bed sheets. Severe VMS was defined as sensation of intense heat with sweating, caused disruption of activity. If at night, participant woke up hot and was sweating and needed to take action (e.g., remove layers of clothes, open the window, or get out of bed). Severity was zero for participants that had no mild or moderate or severe VMS. Higher scores indicates greater severity.
Time frame: Baseline and 24 weeks of fezolinetant exposure (week 36 for arms Placebo/Fezolinetant 30 mg and Placebo/Fezolinetant 45 mg)
Number of Participants in Each Category of Patient's Global Impression of Change (PGIC) in VMS at Each Visit
The PGI is comprised of 2 companion 1-item PRO measures analogous to the Clinical Global Impression (CGI) scales. These measures provide brief, stand-alone global assessments prior to and after initiating a study medication. Patient-perceived change from the initiation of treatment (PGI-C)-VMS is used to evaluate meaningful within-person changes over time in VMS. This measure provides patient-perceived change from the initiation of treatment. The PGI-C VMS asks: "Compared to the beginning of this study, how would you rate your HFs/night sweats now?" Subject ratings range from (1) much better to (7) much worse. Participant ratings range from 1=much better, 2= moderately better, 3= a little better, 4= no change, 5= a little worse, 6= moderately worse, 7= much worse.
Time frame: Weeks 4, 12, 16, 20, 24, 28, 32, 36, 40, 44, 52 of fezolinetant exposure (weeks 16, 24, 28, 32, 36, 40, 44, 48 and 52 for arms Placebo/Fezolinetant 30 mg and Placebo/Fezolinetant 45 mg)
Number of Participants With Adverse Events
An AE is any untoward medical occurrence in a participant administered a study drug, \& which does not necessarily have to have a causal relationship with treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom or disease temporally associated with use of a medicinal product (mp) whether or not considered related to the mp. An AE is considered "serious" if it results in death, is life-threatening, results in persistent or significant disability/incapacity or substantial disruption of the ability to conduct normal life functions, Results in congenital anomaly or birth defect, requires inpatient hospitalization or leads to prolongation of hospitalization, hospitalization for treatment/observation/examination caused by AE is to be considered as serious, discontinuation due to increases in liver enzymes, other medically important events. TEAE was defined as an AE observed from first dose date up to 21 days after last dose.
Time frame: From first dose date up to 21 days after last dose (up to 55 weeks)
Postmenopausal women participants 40 to 65 years of age who had moderate to severe vasomotor symptoms (VMS) and seeking treatment or relief for VMS associated with menopause, confirmed as menopausal, had to have 7 to 8 moderate to severe VMS per day within the 10 days prior to randomization and who met the inclusion criteria and none of the exclusion criteria were enrolled in this study.
| Milestone | Double-blind Period: Placebo | Double-blind Period: Fezolinetant 30 mg/Extension Period: Fezolinetant 30 mg | Double-blind Period: Fezolinetant 45 mg/Extension Period: Fezolinetant 45 mg | Double-blind Period: Placebo/Extension Period: Fezolinetant 30 mg | Double-blind Period: Placebo/Extension Period: Fezolinetant 45 mg |
|---|---|---|---|---|---|
| Started | 168 | 166 | 167 | 0 | 0 |
| Treated | 167 | 166 | 167 | 0 | 0 |
| Completed | 151 | 152 | 155 | 0 | 0 |
| Not completed | 17 | 14 | 12 | 0 | 0 |
| Withdrew: Adverse event | 1 | 1 | 2 | 0 | 0 |
| Withdrew: Lost to follow-up | 2 | 1 | 2 | 0 | 0 |
| Withdrew: Protocol deviation | 1 | 5 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 11 | 6 | 6 | 0 | 0 |
| Withdrew: Miscellaneous | 2 | 1 | 2 | 0 | 0 |
| Milestone | Double-blind Period: Placebo | Double-blind Period: Fezolinetant 30 mg/Extension Period: Fezolinetant 30 mg | Double-blind Period: Fezolinetant 45 mg/Extension Period: Fezolinetant 45 mg | Double-blind Period: Placebo/Extension Period: Fezolinetant 30 mg | Double-blind Period: Placebo/Extension Period: Fezolinetant 45 mg |
|---|---|---|---|---|---|
| Started | 0 | 152 | 154 | 76 | 75 |
| Completed | 0 | 125 | 132 | 63 | 63 |
| Not completed | 0 | 27 | 22 | 13 | 12 |
| Withdrew: Adverse event | 0 | 4 | 4 | 2 | 3 |
| Withdrew: Death | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Lost to follow-up | 0 | 2 | 1 | 2 | 1 |
| Withdrew: Protocol deviation | 0 | 0 | 2 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 17 | 14 | 9 | 5 |
| Withdrew: Miscellaneous | 0 | 4 | 1 | 0 | 2 |
The frequency of moderate to severe VMS was the number of moderate to severe VMS per 24 hours. A daily frequency per week was derived by taking the mean of the data over 7 days. Moderate VMS was defined as sensation of heat with sweating/dampness, but was able to continue activity. If at night, participant woke up because she was feeling hot and/or was sweating, but no action was necessary other than rearranging the bed sheets. Severe VMS was defined as sensation of intense heat with sweating, caused disruption of activity. If at night, participant woke up hot and was sweating and needed to take action (e.g., remove layers of clothes, open the window, or get out of bed). Baseline was the average number of moderate to severe VMS per 24 hours based on the non-missing values in the 10 days immediately prior to randomization.
| VMS per day | Double-blind Period: Placebo | Double-blind Period: Fezolinetant 30 mg | Double-blind Period: Fezolinetant 45 mg |
|---|---|---|---|
| Change From Baseline in The Mean Frequency of Moderate to Severe VMS at Week 4 | -3.72 ± 0.33 | -5.53 ± 0.33 | -6.26 ± 0.33 |
The frequency of moderate to severe VMS was the number of moderate to severe VMS per 24 hours. A daily frequency per week was derived by taking the mean of the data over 7 days. Moderate VMS was defined as sensation of heat with sweating/dampness, but was able to continue activity. If at night, participant woke up because she was feeling hot and/or was sweating, but no action was necessary other than rearranging the bed sheets. Severe VMS was defined as sensation of intense heat with sweating, caused disruption of activity. If at night, participant woke up hot and was sweating and needed to take action (e.g., remove layers of clothes, open the window, or get out of bed). Baseline was the average number of moderate to severe VMS per 24 hours based on the non-missing values in the 10 days immediately prior to randomization.
| VMS per day | Double-blind Period: Placebo | Double-blind Period: Fezolinetant 30 mg | Double-blind Period: Fezolinetant 45 mg |
|---|---|---|---|
| Change From Baseline in The Mean Frequency of Moderate to Severe VMS at Week 12 | -4.97 ± 0.39 | -6.83 ± 0.39 | -7.50 ± 0.39 |
Severity of moderate to severe VMS per day at post baseline visit was calculated as follows: \[(number of mild hot flashes per day x 1) + (number of moderate hot flashes per day x 2) + (number of severe hot flashes per day x 3)\]/Total number of daily mild/moderate/severe hot flashes Moderate VMS was defined as sensation of heat with sweating/dampness, but was able to continue activity. If at night, participant woke up because she was feeling hot and/or was sweating, but no action was necessary other than rearranging the bed sheets. Severe VMS was defined as sensation of intense heat with sweating, caused disruption of activity. If at night, participant woke up hot and was sweating and needed to take action (e.g., remove layers of clothes, open the window, or get out of bed). Severity was zero for participants that had no mild or moderate or severe VMS. Higher scores indicates greater severity.
| Score on a scale | Double-blind Period: Placebo | Double-blind Period: Fezolinetant 30 mg | Double-blind Period: Fezolinetant 45 mg |
|---|---|---|---|
| Change From Baseline in The Mean Severity of Moderate to Severe VMS at Week 4 | -0.32 ± 0.05 | -0.47 ± 0.05 | -0.61 ± 0.05 |
Severity of moderate to severe VMS per day at post baseline visit was calculated as follows: \[(number of mild hot flashes per day x 1) + (number of moderate hot flashes per day x 2) + (number of severe hot flashes per day x 3)\]/Total number of daily mild/moderate/severe hot flashes Moderate VMS was defined as sensation of heat with sweating/dampness, but was able to continue activity. If at night, participant woke up because she was feeling hot and/or was sweating, but no action was necessary other than rearranging the bed sheets. Severe VMS was defined as sensation of intense heat with sweating, caused disruption of activity. If at night, participant woke up hot and was sweating and needed to take action (e.g., remove layers of clothes, open the window, or get out of bed). Severity was zero for participants that had no mild or moderate or severe VMS. Higher scores indicates greater severity.
| Score on a scale | Double-blind Period: Placebo | Double-blind Period: Fezolinetant 30 mg | Double-blind Period: Fezolinetant 45 mg |
|---|---|---|---|
| Change From Baseline in The Mean Severity of Moderate to Severe VMS at Week 12 | -0.48 ± 0.06 | -0.64 ± 0.06 | -0.77 ± 0.06 |
The PROMIS SD SF 8b assesses self-reported sleep disturbance over the past 7 days and includes perceptions of restless sleep; satisfaction with sleep; refreshing sleep; difficulties sleeping, getting to sleep or staying asleep; amount of sleep; and sleep quality. Because it assesses the participants experience of sleep disturbance, the measure does not focus on specific sleep-disorder symptoms or ask participants to report objective measures of sleep (e.g., total amount of sleep, time to fall asleep and amount of wakefulness during sleep). Responses to each of the 8 items range from 1 (no disturbed sleep) to 5 (disturbed sleep), and the range of possible summed raw scores is 8 to 40. Higher scores on the PROMIS SD SF 8b indicate more of the disturbed sleep.
| Score on a scale | Double-blind Period: Placebo | Double-blind Period: Fezolinetant 30 mg | Double-blind Period: Fezolinetant 45 mg |
|---|---|---|---|
| Change From Baseline in The Mean Patient-reported Outcomes Measurement Information System Sleep Disturbance - Short Form 8b (PROMIS SD SF 8b) Total Score at Week 12 | -3.4 ± 0.5 | -4.1 ± 0.5 | -5.5 ± 0.5 |
The frequency of moderate to severe VMS was the number of moderate to severe VMS per 24 hours. A daily frequency per week was derived by taking the mean of the data over 7 days. Moderate VMS was defined as sensation of heat with sweating/dampness, but was able to continue activity. If at night, participant woke up because she was feeling hot and/or was sweating, but no action was necessary other than rearranging the bed sheets. Severe VMS was defined as sensation of intense heat with sweating, caused disruption of activity. If at night, participant woke up hot and was sweating and needed to take action (e.g., remove layers of clothes, open the window, or get out of bed). Baseline was the average number of moderate to severe VMS per 24 hours based on the non-missing values in the 10 days immediately prior to randomization.
| VMS per day | Double-blind Period: Placebo | Double-blind Period: Fezolinetant 30 mg | Double-blind Period: Fezolinetant 45 mg |
|---|---|---|---|
| Week 1 | -2.32 ± 0.28 | -3.62 ± 0.29 | -4.03 ± 0.29 |
| Week 2 | -3.06 ± 0.32 | -4.82 ± 0.32 | -5.03 ± 0.32 |
| Week 3 | -3.56 ± 0.32 | -5.29 ± 0.32 | -5.95 ± 0.32 |
| Week 5 | -4.05 ± 0.34 | -5.89 ± 0.34 | -6.71 ± 0.34 |
| Week 6 | -4.25 ± 0.33 | -6.03 ± 0.33 | -6.91 ± 0.33 |
| Week 7 | -4.44 ± 0.35 | -6.24 ± 0.35 | -6.78 ± 0.35 |
| Week 8 | -4.48 ± 0.37 | -6.25 ± 0.37 | -6.86 ± 0.37 |
| Week 9 | -4.88 ± 0.38 | -6.54 ± 0.38 | -7.39 ± 0.38 |
| Week 10 | -4.83 ± 0.38 | -6.74 ± 0.38 | -7.47 ± 0.38 |
| Week 11 | -4.90 ± 0.38 | -6.76 ± 0.38 | -7.46 ± 0.37 |
Severity of moderate to severe VMS per day at post baseline visit was calculated as follows: \[(number of mild hot flashes per day x 1) + (number of moderate hot flashes per day x 2) + (number of severe hot flashes per day x 3)\]/Total number of daily mild/moderate/severe hot flashes Moderate VMS was defined as sensation of heat with sweating/dampness, but was able to continue activity. If at night, participant woke up because she was feeling hot and/or was sweating, but no action was necessary other than rearranging the bed sheets. Severe VMS was defined as sensation of intense heat with sweating, caused disruption of activity. If at night, participant woke up hot and was sweating and needed to take action (e.g., remove layers of clothes, open the window, or get out of bed). Severity was zero for participants that had no mild or moderate or severe VMS. Higher scores indicates greater severity.
| Score on a scale | Double-blind Period: Placebo | Double-blind Period: Fezolinetant 30 mg | Double-blind Period: Fezolinetant 45 mg |
|---|---|---|---|
| Week 1 | -0.18 ± 0.03 | -0.32 ± 0.03 | -0.34 ± 0.03 |
| Week 2 | -0.24 ± 0.04 | -0.41 ± 0.04 | -0.42 ± 0.04 |
| Week 3 | -0.31 ± 0.04 | -0.42 ± 0.04 | -0.54 ± 0.04 |
| Week 5 | -0.37 ± 0.05 | -0.53 ± 0.05 | -0.66 ± 0.05 |
| Week 6 | -0.37 ± 0.05 | -0.55 ± 0.05 | -0.65 ± 0.05 |
| Week 7 | -0.42 ± 0.05 | -0.58 ± 0.05 | -0.70 ± 0.05 |
| Week 8 | -0.43 ± 0.05 | -0.56 ± 0.05 | -0.69 ± 0.05 |
| Week 9 | -0.46 ± 0.06 | -0.59 ± 0.06 | -0.74 ± 0.06 |
| Week 10 | -0.45 ± 0.06 | -0.64 ± 0.06 | -0.76 ± 0.06 |
| Week 11 | -0.46 ± 0.06 | -0.67 ± 0.06 | -0.77 ± 0.06 |
The frequency of moderate to severe VMS was the number of moderate to severe VMS per 24 hours. A daily frequency per week was derived by taking the mean of the data over 7 days. Moderate VMS was defined as sensation of heat with sweating/dampness, but was able to continue activity. If at night, participant woke up because she was feeling hot and/or was sweating, but no action was necessary other than rearranging the bed sheets. Severe VMS was defined as sensation of intense heat with sweating, caused disruption of activity. If at night, participant woke up hot and was sweating and needed to take action (e.g., remove layers of clothes, open the window, or get out of bed). Baseline was the average number of moderate to severe VMS per 24 hours based on the non-missing values in the 10 days immediately prior to randomization.
| Percent change | Double-blind Period: Placebo | Double-blind Period: Fezolinetant 30 mg | Double-blind Period: Fezolinetant 45 mg |
|---|---|---|---|
| Week 1 | -20.82 ± 2.42 | -32.98 ± 2.43 | -36.50 ± 2.45 |
| Week 2 | -29.21 ± 2.69 | -43.82 ± 2.69 | -45.16 ± 2.71 |
| Week 3 | -33.17 ± 2.76 | -48.68 ± 2.75 | -53.42 ± 2.76 |
| Week 4 | -34.72 ± 2.78 | -51.06 ± 2.77 | -56.37 ± 2.77 |
| Week 5 | -37.88 ± 2.75 | -53.50 ± 2.75 | -60.76 ± 2.74 |
| Week 6 | -39.64 ± 2.73 | -54.42 ± 2.73 | -62.30 ± 2.73 |
| Week 7 | -40.91 ± 2.84 | -55.88 ± 2.84 | -62.38 ± 2.83 |
| Week 8 | -41.84 ± 2.86 | -56.22 ± 2.86 | -62.42 ± 2.84 |
| Week 9 | -45.87 ± 2.88 | -58.01 ± 2.88 | -65.60 ± 2.86 |
| Week 10 | -45.58 ± 2.83 | -59.98 ± 2.82 | -65.68 ± 2.81 |
| Week 11 | -45.41 ± 2.88 | -60.37 ± 2.87 | -65.56 ± 2.86 |
| Week 12 | -46.91 ± 2.87 | -60.55 ± 2.87 | -65.85 ± 2.85 |
The frequency of moderate to severe VMS was the number of moderate to severe VMS per 24 hours. A daily frequency per week was derived by taking the mean of the data over 7 days. Moderate VMS was defined as sensation of heat with sweating/dampness, but was able to continue activity. If at night, participant woke up because she was feeling hot and/or was sweating, but no action was necessary other than rearranging the bed sheets. Severe VMS was defined as sensation of intense heat with sweating, caused disruption of activity. If at night, participant woke up hot and was sweating and needed to take action (e.g., remove layers of clothes, open the window, or get out of bed). Baseline was the average number of moderate to severe VMS per 24 hours based on the non-missing values in the 10 days immediately prior to randomization. Participant has \>=50% reduction from baseline to each post baseline week for the frequency of moderate to severe VMS.
| Participants | Double-blind Period: Placebo | Double-blind Period: Fezolinetant 30 mg | Double-blind Period: Fezolinetant 45 mg |
|---|---|---|---|
| Week 1 | 28 | 46 | 58 |
| Week 2 | 39 | 71 | 71 |
| Week 3 | 48 | 81 | 89 |
| Week 4 | 44 | 84 | 88 |
| Week 5 | 54 | 84 | 98 |
| Week 6 | 53 | 81 | 95 |
| Week 7 | 55 | 84 | 92 |
| Week 8 | 56 | 81 | 103 |
| Week 9 | 64 | 84 | 98 |
| Week 10 | 62 | 85 | 103 |
| Week 11 | 60 | 94 | 105 |
| Week 12 | 71 | 84 | 101 |
The frequency of moderate to severe VMS was the number of moderate to severe VMS per 24 hours. A daily frequency per week was derived by taking the mean of the data over 7 days. Moderate VMS was defined as sensation of heat with sweating/dampness, but was able to continue activity. If at night, participant woke up because she was feeling hot and/or was sweating, but no action was necessary other than rearranging the bed sheets. Severe VMS was defined as sensation of intense heat with sweating, caused disruption of activity. If at night, participant woke up hot and was sweating and needed to take action (e.g., remove layers of clothes, open the window, or get out of bed). Baseline was the average number of moderate to severe VMS per 24 hours based on the non-missing values in the 10 days immediately prior to randomization. Participant has 100% reduction from baseline to each post baseline week for the frequency of moderate to severe VMS.
| Participants | Double-blind Period: Placebo | Double-blind Period: Fezolinetant 30 mg | Double-blind Period: Fezolinetant 45 mg |
|---|---|---|---|
| Week 1 | 1 | 1 | 3 |
| Week 2 | 3 | 8 | 4 |
| Week 3 | 5 | 4 | 11 |
| Week 4 | 3 | 10 | 17 |
| Week 5 | 3 | 12 | 11 |
| Week 6 | 9 | 12 | 17 |
| Week 7 | 9 | 13 | 18 |
| Week 8 | 10 | 17 | 22 |
| Week 9 | 9 | 14 | 18 |
| Week 10 | 11 | 17 | 25 |
| Week 11 | 9 | 15 | 28 |
| Week 12 | 9 | 15 | 25 |
The frequency of moderate to severe VMS was the number of moderate to severe VMS per 24 hours. A daily frequency per week was derived by taking the mean of the data over 7 days. Moderate VMS was defined as sensation of heat with sweating/dampness, but was able to continue activity. If at night, participant woke up because she was feeling hot and/or was sweating, but no action was necessary other than rearranging the bed sheets. Severe VMS was defined as sensation of intense heat with sweating, caused disruption of activity. If at night, participant woke up hot and was sweating and needed to take action (e.g., remove layers of clothes, open the window, or get out of bed). Baseline was the average number of moderate to severe VMS per 24 hours based on the non-missing values in the 10 days immediately prior to randomization.
| VMS per day | Double-blind Period: Fezolinetant 30 mg/Extension Period: Fezolinetant 30 mg | Double-blind Period: Fezolinetant 45 mg/Extension Period: Fezolinetant 45 mg | Double-blind Period: Placebo/Extension Period: Fezolinetant 30 mg | Double-blind Period: Placebo/Extension Period: Fezolinetant 45 mg |
|---|---|---|---|---|
| Change From Baseline in The Mean Frequency of Moderate, and Severe VMS at Week 24 | -7.86 ± 4.21 | -7.96 ± 4.53 | -9.01 ± 5.80 | -7.08 ± 5.40 |
Severity of moderate to severe VMS per day at post baseline visit was calculated as follows: \[(number of mild hot flashes per day x 1) + (number of moderate hot flashes per day x 2) + (number of severe hot flashes per day x 3)\]/Total number of daily mild/moderate/severe hot flashes Moderate VMS was defined as sensation of heat with sweating/dampness, but was able to continue activity. If at night, participant woke up because she was feeling hot and/or was sweating, but no action was necessary other than rearranging the bed sheets. Severe VMS was defined as sensation of intense heat with sweating, caused disruption of activity. If at night, participant woke up hot and was sweating and needed to take action (e.g., remove layers of clothes, open the window, or get out of bed). Severity was zero for participants that had no mild or moderate or severe VMS. Higher scores indicates greater severity.
| Score on a scale | Double-blind Period: Fezolinetant 30 mg/Extension Period: Fezolinetant 30 mg | Double-blind Period: Fezolinetant 45 mg/Extension Period: Fezolinetant 45 mg | Double-blind Period: Placebo/Extension Period: Fezolinetant 30 mg | Double-blind Period: Placebo/Extension Period: Fezolinetant 45 mg |
|---|---|---|---|---|
| Change From Baseline in The Mean Severity of Moderate, and Severe VMS at Week 24 | -0.85 ± 0.88 | -0.90 ± 0.80 | -0.78 ± 0.85 | -0.95 ± 0.88 |
The PGI is comprised of 2 companion 1-item PRO measures analogous to the Clinical Global Impression (CGI) scales. These measures provide brief, stand-alone global assessments prior to and after initiating a study medication. Patient-perceived change from the initiation of treatment (PGI-C)-VMS is used to evaluate meaningful within-person changes over time in VMS. This measure provides patient-perceived change from the initiation of treatment. The PGI-C VMS asks: "Compared to the beginning of this study, how would you rate your HFs/night sweats now?" Subject ratings range from (1) much better to (7) much worse. Participant ratings range from 1=much better, 2= moderately better, 3= a little better, 4= no change, 5= a little worse, 6= moderately worse, 7= much worse.
| Participants | Double-blind Period: Placebo | Double-blind Period: Fezolinetant 30 mg/Extension Period: Fezolinetant 30 mg | Double-blind Period: Fezolinetant 45 mg/Extension Period: Fezolinetant 45 mg | Double-blind Period: Placebo/Extension Period: Fezolinetant 30 mg | Double-blind Period: Placebo/Extension Period: Fezolinetant 45 mg |
|---|---|---|---|---|---|
| Week 4: Much better | 25 | 61 | 68 | — | 2 |
| Week 4:Moderately better | 23 | 21 | 32 | — | 0 |
| Week 4:A little better | 46 | 42 | 42 | — | 1 |
| Week 4:No change | 43 | 29 | 16 | — | 0 |
| Week 4:A little worse | 6 | 2 | 0 | — | 0 |
| Week 4:Moderately worse | 6 | 0 | 0 | — | 0 |
| Week 4:Much worse | 2 | 0 | 1 | — | 0 |
| Week 12: Much better | 35 | 68 | 71 | 40 | 30 |
| Week 12: Moderately better | 24 | 25 | 37 | 11 | 18 |
| Week 12: A little better | 36 | 29 | 32 | 11 | 10 |
| Week 12: No change | 39 | 19 | 8 | 4 | 4 |
| Week 12: A little worse | 6 | 1 | 1 | 1 | 4 |
| Week 12: Moderately worse | 2 | 2 | 0 | 0 | 1 |
| Week 12: Much worse | 2 | 1 | 0 | 0 | 2 |
| Week 16: Much better | — | 0 | 2 | — | — |
| Week 16: Moderately better | — | 0 | 0 | — | — |
| Week 16: A little better | — | 0 | 0 | — | — |
| Week 16: No change | — | 0 | 0 | — | — |
| Week 16: A little worse | — | 0 | 0 | — | — |
| Week 16: Moderately worse | — | 0 | 0 | — | — |
| Week 16: Much worse | — | 1 | 0 | — | — |
| Week 20: Much better | — | 1 | — | — | — |
| Week 20: Moderately better | — | 0 | — | — | — |
| Week 20: A little better | — | 0 | — | — | — |
| Week 20: No change | — | 1 | — | — | — |
| Week 20: A little worse | — | 0 | — | — | — |
| Week 20: Moderately worse | — | 0 | — | — | — |
| Week 20: Much worse | — | 0 | — | — | — |
| Week 24: Much better | — | 68 | 76 | 0 | — |
| Week 24: Moderately better | — | 31 | 33 | 1 | — |
| Week 24: A little better | — | 22 | 22 | 0 | — |
| Week 24: No change | — | 9 | 4 | 0 | — |
| Week 24: A little worse | — | 1 | 3 | 0 | — |
| Week 24: Moderately worse | — | 2 | 1 | 0 | — |
| Week 24: Much worse | — | 1 | 0 | 0 | — |
| Week 28: Much better | — | 1 | 0 | 1 | — |
| Week 28: Moderately better | — | 0 | 0 | 0 | — |
| Week 28: A little better | — | 0 | 0 | 0 | — |
| Week 28: No change | — | 0 | 0 | 0 | — |
| Week 28: A little worse | — | 0 | 0 | 0 | — |
| Week 28: Moderately worse | — | 0 | 0 | 0 | — |
| Week 28: Much worse | — | 0 | 1 | 0 | — |
| Week 32: Much better | — | — | 1 | — | — |
| Week 32: Moderately better | — | — | 0 | — | — |
| Week 32: A little better | — | — | 0 | — | — |
| Week 32: No change | — | — | 0 | — | — |
| Week 32: A little worse | — | — | 0 | — | — |
| Week 32: Moderately worse | — | — | 0 | — | — |
| Week 32: Much worse | — | — | 0 | — | — |
| Week 36: Much better | — | 0 | — | — | — |
| Week 36: Moderately better | — | 1 | — | — | — |
| Week 36: A little better | — | 0 | — | — | — |
| Week 36: No change | — | 0 | — | — | — |
| Week 36: A little worse | — | 0 | — | — | — |
| Week 36: Moderately worse | — | 0 | — | — | — |
| Week 36: Much worse | — | 0 | — | — | — |
| Week 40: Much better | — | — | — | 33 | 31 |
| Week 40: Moderately better | — | — | — | 14 | 13 |
| Week 40: A little better | — | — | — | 5 | 8 |
| Week 40: No change | — | — | — | 3 | 2 |
| Week 40: A little worse | — | — | — | 0 | 0 |
| Week 40: Moderately worse | — | — | — | 0 | 0 |
| Week 40: Much worse | — | — | — | 0 | 0 |
| Week 44: Much better | — | 2 | — | — | — |
| Week 44: Moderately better | — | 0 | — | — | — |
| Week 44: A little better | — | 0 | — | — | — |
| Week 44: No change | — | 0 | — | — | — |
| Week 44: A little worse | — | 0 | — | — | — |
| Week 44: Moderately worse | — | 0 | — | — | — |
| Week 44: Much worse | — | 0 | — | — | — |
| Week 52: Much better | — | 60 | 77 | — | — |
| Week 52: Moderately better | — | 25 | 22 | — | — |
| Week 52: A little better | — | 14 | 13 | — | — |
| Week 52: No change | — | 4 | 2 | — | — |
| Week 52: A little worse | — | 1 | 0 | — | — |
| Week 52: Moderately worse | — | 1 | 0 | — | — |
| Week 52: Much worse | — | 2 | 2 | — | — |
An AE is any untoward medical occurrence in a participant administered a study drug, \& which does not necessarily have to have a causal relationship with treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom or disease temporally associated with use of a medicinal product (mp) whether or not considered related to the mp. An AE is considered "serious" if it results in death, is life-threatening, results in persistent or significant disability/incapacity or substantial disruption of the ability to conduct normal life functions, Results in congenital anomaly or birth defect, requires inpatient hospitalization or leads to prolongation of hospitalization, hospitalization for treatment/observation/examination caused by AE is to be considered as serious, discontinuation due to increases in liver enzymes, other medically important events. TEAE was defined as an AE observed from first dose date up to 21 days after last dose.
| Participants | Double-blind Period: Placebo | Double-blind Period: Fezolinetant 30 mg/Extension Period: Fezolinetant 30 mg | Double-blind Period: Fezolinetant 45 mg/Extension Period: Fezolinetant 45 mg | Double-blind Period: Placebo/Extension Period: Fezolinetant 30 mg | Double-blind Period: Placebo/Extension Period: Fezolinetant 45 mg |
|---|---|---|---|---|---|
| Treatment Emergent Adverse Events (TEAE) | 54 | 107 | 106 | 43 | 45 |
| Drug-related TEAE | 11 | 33 | 30 | 8 | 8 |
| Serious TEAE | 0 | 9 | 8 | 2 | 4 |
| Drug-related serious TEAE | 0 | 0 | 1 | 0 | 1 |
| TEAE leading to death | 0 | 0 | 0 | 0 | 1 |
| Drug-related TEAE leading to death | 0 | 0 | 0 | 0 | 0 |
| TEAE leading to withdrawal of treatment | 1 | 4 | 7 | 2 | 3 |
| Drug-related TEAE leading to withdrawal of treatment | 0 | 1 | 6 | 1 | 2 |
| Death | 0 | 0 | 0 | 0 | 1 |
Collected over From first dose date up to 21 days after last dose (up to 55 weeks). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Double-blind Period: Placebo | 0/167 (0%) | 0/167 (0%) | 6/167 (3.6%) |
| Double-blind Period: Fezolinetant 30 mg/Extension Period: Fezolinetant 30 mg | 0/166 (0%) | 9/166 (5.4%) | 20/166 (12%) |
| Double-blind Period: Fezolinetant 45 mg/Extension Period: Fezolinetant 45 mg | 0/167 (0%) | 8/167 (4.8%) | 34/167 (20.4%) |
| Double-blind Period: Placebo/Extension Period: Fezolinetant 30 mg | 0/76 (0%) | 2/76 (2.6%) | 10/76 (13.2%) |
| Double-blind Period: Placebo/Extension Period: Fezolinetant 45 mg | 1/75 (1.3%) | 4/75 (5.3%) | 12/75 (16%) |
| Event | Double-blind Period: Placebo | Double-blind Period: Fezolinetant 30 mg/Extension Period: Fezolinetant 30 mg | Double-blind Period: Fezolinetant 45 mg/Extension Period: Fezolinetant 45 mg | Double-blind Period: Placebo/Extension Period: Fezolinetant 30 mg | Double-blind Period: Placebo/Extension Period: Fezolinetant 45 mg |
|---|---|---|---|---|---|
| HepatotoxicityHepatobiliary disorders | 0/167 | 0/166 | 0/167 | 0/76 | 1/75 |
| Foot fractureInjury, poisoning and procedural complications | 0/167 | 0/166 | 0/167 | 0/76 | 1/75 |
| Multiple injuriesInjury, poisoning and procedural complications | 0/167 | 0/166 | 0/167 | 0/76 | 1/75 |
| Uterine leiomyomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/167 | 0/166 | 0/167 | 0/76 | 1/75 |
| Atrial fibrillationCardiac disorders | 0/167 | 1/166 | 0/167 | 1/76 | 0/75 |
| Invasive breast carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/167 | 0/166 | 0/167 | 1/76 | 0/75 |
| COVID-19Infections and infestations | 0/167 | 2/166 | 0/167 | 0/76 | 0/75 |
| Coronary artery diseaseCardiac disorders | 0/167 | 1/166 | 0/167 | 0/76 | 0/75 |
| Non-cardiac chest painGeneral disorders | 0/167 | 1/166 | 0/167 | 0/76 | 0/75 |
| Cholecystitis acuteHepatobiliary disorders | 0/167 | 1/166 | 0/167 | 0/76 | 0/75 |
| Event | Double-blind Period: Placebo | Double-blind Period: Fezolinetant 30 mg/Extension Period: Fezolinetant 30 mg | Double-blind Period: Fezolinetant 45 mg/Extension Period: Fezolinetant 45 mg | Double-blind Period: Placebo/Extension Period: Fezolinetant 30 mg | Double-blind Period: Placebo/Extension Period: Fezolinetant 45 mg |
|---|---|---|---|---|---|
| COVID-19Infections and infestations | 1/167 | 8/166 | 15/167 | 4/76 | 3/75 |
| HeadacheNervous system disorders | 4/167 | 8/166 | 12/167 | 1/76 | 4/75 |
| Blood creatine phosphokinase increasedInvestigations | 0/167 | 2/166 | 3/167 | 1/76 | 5/75 |
| Hot flushVascular disorders | 1/167 | 3/166 | 7/167 | 4/76 | 0/75 |
All randomized participants.
| Age, Continuous(Years) | Double-blind Period: Placebo | Double-blind Period: Fezolinetant 30 mg/Extension Period: Fezolinetant 30 mg | Double-blind Period: Fezolinetant 45 mg/Extension Period: Fezolinetant 45 mg | Total |
|---|---|---|---|---|
| Mean | 54.6 ± 4.6 | 53.9 ± 4.9 | 54.3 ± 5.4 | 54.3 ± 5 |
| Sex: Female, Male(Participants) | Double-blind Period: Placebo | Double-blind Period: Fezolinetant 30 mg/Extension Period: Fezolinetant 30 mg | Double-blind Period: Fezolinetant 45 mg/Extension Period: Fezolinetant 45 mg | Total |
|---|---|---|---|---|
| Female | 168 | 166 | 167 | 501 |
| Male | 0 | 0 | 0 | 0 |
| Ethnicity (NIH/OMB)(Participants) | Double-blind Period: Placebo | Double-blind Period: Fezolinetant 30 mg/Extension Period: Fezolinetant 30 mg | Double-blind Period: Fezolinetant 45 mg/Extension Period: Fezolinetant 45 mg | Total |
|---|---|---|---|---|
| Hispanic or Latino | 33 | 34 | 41 | 108 |
| Not Hispanic or Latino | 134 | 132 | 126 | 392 |
| Unknown or Not Reported | 1 | 0 | 0 | 1 |
| Race (NIH/OMB)(Participants) | Double-blind Period: Placebo | Double-blind Period: Fezolinetant 30 mg/Extension Period: Fezolinetant 30 mg | Double-blind Period: Fezolinetant 45 mg/Extension Period: Fezolinetant 45 mg | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 1 | 1 |
| Asian | 1 | 0 | 0 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 31 | 35 | 33 | 99 |
| White | 135 | 131 | 132 | 398 |
| More than one race | 1 | 0 | 1 | 2 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Frequency of Moderate and Severe VMS per 24 hours(VMS per day) | Double-blind Period: Placebo | Double-blind Period: Fezolinetant 30 mg/Extension Period: Fezolinetant 30 mg | Double-blind Period: Fezolinetant 45 mg/Extension Period: Fezolinetant 45 mg | Total |
|---|---|---|---|---|
| Mean | 11.59 ± 5.02 | 11.23 ± 4.88 | 11.79 ± 8.26 | 11.54 ± 6.25 |
| Severity of Moderate and Severe VMS per 24 hours(Score on a scale) | Double-blind Period: Placebo | Double-blind Period: Fezolinetant 30 mg/Extension Period: Fezolinetant 30 mg | Double-blind Period: Fezolinetant 45 mg/Extension Period: Fezolinetant 45 mg | Total |
|---|---|---|---|---|
| Mean | 2.41 ± 0.32 | 2.44 ± 0.33 | 2.41 ± 0.34 | 2.42 ± 0.33 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Access to anonymized individual participant level data collected during the study, in addition to study-related supporting documentation, is planned for studies conducted with approved product indications and formulations, as well as products terminated during development. Studies conducted with product indications or formulations that remain active in development are assessed after study completion to determine if Individual Participant Data can be shared. Further details on Astellas' data sharing policy can be found at https://www.clinicaltrials.astellas.com/transparency/.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Access to participant level data is offered to researchers after publication of the primary manuscript (if applicable) and is available as long as Astellas has legal authority to provide the data.
Access criteria: Researchers must submit a proposal to conduct a scientifically relevant analysis of the study data. The research proposal is reviewed by an Independent Research Panel. If the proposal is approved, access to the study data is provided in a secure data sharing environment after receipt of a signed Data Sharing Agreement.
Data sharing details ↗ · www.clinicaltrials.astellas.com
Ran from Jul 2019 to primary completion in Jul 2020, 12 months.
Results were first posted in Jun 2022, 1 year 10 months after primary completion. A results delay was requested in Jul 2021.
Of 23 phase 3 interventional studies under Hot Flashes, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 29. This study's 12 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Fezolinetant
Astellas Pharma Global Development, Inc. →